CHRNA7 and Alzheimer disease: However, it would be very informative to track changes in individual patients longitudinally using 18F-ASEM, in relation to neuropathological biomarkers and cognitive status, to better understand the temporal relationship between α7nAChR changes and other pathological alterations in AD.